Journal of Hematology & Thromboembolic Diseases
Open Access

John Sarantopoulos

Publications

• Review Article
  Role of Novel Oral Anticoagulants in Primary and Secondary Thromboprophylaxis in Cancer
  Author(s): Elizabeth Bowhay-Carnes, Anand Karnad, Subrata Haldar, John Sarantopoulos and Sumit MadanElizabeth Bowhay-Carnes, Anand Karnad, Subrata Haldar, John Sarantopoulos and Sumit Madan
  
  The development of venous thromboembolism is one of the major causes of morbidity and mortality in patients with cancer. The standard treatment of deep venous thrombosis or pulmonary embolism occurring in patients with active malignancy remains the use of low molecular weight heparins. However, in clinical practice, practitioners are frequently asked about the efficacy and safety of various new oral anticoagulants in cancer patients. In the United States, there are currently 4 different novel oral anticoagulants commercially available with the indication of the treatment of acute venous thromboembolism. These include dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa). Use of these new medications is appealing due to the ease of administration, avoidance of injections, ability to use in patients with decreased renal or liver function, and consistent.. View More»
  DOI: 10.4172/2329-8790.1000222

  Abstract PDF

Relevant Topics